Prohibits drug manufacturers from placing conditions that limit covered entities’ ability to buy outpatient drugs at the 340B discounted ceiling price, including when drugs are dispensed through outside or contract pharmacies. Establishes large civil money penalties for intentional violations and requires the Secretary of HHS to issue regulations within 180 days so covered entities can make claims for violations.